Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer

[at noodls] – Research presented at 2012 SABCS examines cardiac safety profile of MM-302, a new HER2-targeted Liposomal Doxorubicin Agent….This is an abstract of the original noodl. To continue reading this document, … more

View todays social media effects on MACK

View the latest stocks trending across Twitter. Click to view dashboard